New drug candidate shows potential for faster wound healing

Researchers developed NCGC-6782, a selective LATS1/2 inhibitor that promotes cell proliferation and skin regeneration.

Researchers discovered NCGC-6782, a LATS1/2 inhibitor with wound healing potential. This molecule shows robust proproliferative activity.

The work began with large-scale profiling of 257 kinase inhibitors. This mapping revealed domains of promiscuity and pockets of selectivity.

Scientists used the AKT inhibitor AT-7867 as a starting point. They used scaffold hopping and property-based optimization to find NCGC-6782.

NCGC-6782 inhibited LATS1/2 activity and reduced YAP phosphorylation. This led to rapid YAP nuclear translocation and transactivation of YAP-target genes.

In skin injury models, NCGC-6782 accelerated proliferative regeneration. It significantly shortened wound-closure time without evidence of systemic toxicity.

The drug showed favorable pharmacokinetic (PK) profiles after intraperitoneal (IP), intravenous (IV), or oral (PO) dosing. It may have potential for regenerative medicine applications.

Key facts

  • NCGC-6782 is a selective LATS1/2 kinase inhibitor.
  • The inhibitor accelerated wound-closure time in skin injury models.
  • NCGC-6782 showed favorable pharmacokinetic (PK) profiles after oral (PO) dosing.
  • The drug promotes the transactivation of YAP-target genes.

All sections

Edition